Chemistree Technology Inc (CSE:CHM) (OTCMKST:CHMJF) says investee company ImmunoFlex, a life sciences company developing clinically validated, pharmaceutical-grade natural health products based on advancements in genomics research, has received approval for its Flex 10 product from Health Canada.
"At ImmunoFlex, we work with the immune system to strengthen, support, and enhance our body's natural surveillance and response system," said ImmunoFlex CEO Chris Wagner in a statement.
READ: Chemistree to unveil virtual reality tour of Washington State cannabis facility at industry expo
"FLEX 10 is the first product in our line up of products designed to achieve this goal so we could not be more delighted with the Health Canada approval," Wagner noted.
Chemistree President Karl Kottmeier added: "This is great news. We view the approval from Health Canada as a significant milestone for Immunoflex and look forward to announcing further advancements for this and their other products."
FLEX 10 is ImmunoFlex's unique N-Acetyl-L-cysteine formulation in packs of 30-600 mg capsules. FLEX 10 is a powerful antioxidant, specifically packaged in aluminum blisters to reduce the potential for product oxidation.
Contact the author: email@example.com
Follow him on Twitter @PatrickMGraham